ArticleEcancermedicalscience2025
Glassy cell carcinoma of the uterine cervix: a rare entity and literature review.
Article in Ecancermedicalscience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Diagnosis of Rare Cervical Tumors: IECC Classification, HPV Status, and Subtype-Directed Immunohistochemistry, with Treatment Outcomes from a Tertiary Center.Pathogens (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glassy cell carcinoma is an extremely rare entity that occurs in 1% to 2% of all cases of cervical cancer, affects young women with greater predisposition, is related to poor prognosis, and distant metastasis. It correlates strongly with the presence of high-risk human papillomavirus (serotypes 16, 18 and 31) and histologically manifests as ground-glass cells, cytosol with vast granular and dense chromatin with large nuclei and protruding nucleoli. We present a 51-year-old woman who was diagnosed with glassy cell carcinoma of the cervix (before the latest edition of the World Health Organisation classification of tumours) in FIGO stage IB1 that was managed with radical hysterectomy and bilateral pelvic lymph node dissection, whose pathological result shows infiltration of the upper third of the vagina, changing the staging to FIGO IIA-1. She received adjuvant concurrent radiotherapy/chemotherapy with a good response, subsequent controls without signs of recurrence and remained currently alive.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.